OTCMKTS:ESALY

Eisai News Headlines

$67.13
-0.43 (-0.64 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$67.06
Now: $67.13
$68.32
50-Day Range
$66.28
MA: $68.02
$70.38
52-Week Range
$63.85
Now: $67.13
$125.00
Volume7,425 shs
Average Volume9,288 shs
Market Capitalization$19.91 billion
P/E Ratio17.35
Dividend Yield1.92%
Beta0.41

Headlines

Eisai (OTCMKTS ESALY) News Headlines Today

SourceHeadline
Eisai Co., Ltd. (OTCMKTS:ESALY) Short Interest UpdateEisai Co., Ltd. (OTCMKTS:ESALY) Short Interest Update
americanbankingnews.com - April 17 at 2:02 AM
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting - BenzingaEisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting - Benzinga
benzinga.com - April 14 at 3:19 AM
FDA advisers reiterate case against approval of Biogen/Eisais aducanumab for Alzheimers - Seeking AlphaFDA advisers reiterate case against approval of Biogen/Eisai's aducanumab for Alzheimer's - Seeking Alpha
seekingalpha.com - April 1 at 12:01 PM
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries - Yahoo Finance AustraliaKYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries - Yahoo Finance Australia
au.finance.yahoo.com - March 31 at 9:27 AM
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan - Yahoo Finance AustraliaEisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan - Yahoo Finance Australia
au.finance.yahoo.com - March 31 at 9:27 AM
Eisai Co., Ltd. (OTCMKTS:ESALY) Short Interest Down 39.3% in MarchEisai Co., Ltd. (OTCMKTS:ESALY) Short Interest Down 39.3% in March
americanbankingnews.com - March 30 at 3:06 PM
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab - Yahoo Finance AustraliaEisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab - Yahoo Finance Australia
au.finance.yahoo.com - March 30 at 9:26 AM
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 - Yahoo Finance AustraliaEisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 - Yahoo Finance Australia
au.finance.yahoo.com - March 26 at 1:41 PM
Eisai Awarded The New Diversity Management Selection 100 - Yahoo Finance AustraliaEisai Awarded The New Diversity Management Selection 100 - Yahoo Finance Australia
au.finance.yahoo.com - March 22 at 2:09 PM
Eisai Awarded The New Diversity Management Selection 100 - BenzingaEisai Awarded The New Diversity Management Selection 100 - Benzinga
benzinga.com - March 21 at 11:48 PM
Merck Keytruda Plus Eisais Lenvima Cuts Risk Of Death By 38% In Endometrial Cancer Trial Compared To Chemo - Yahoo FinanceMerck' Keytruda Plus Eisai's Lenvima Cuts Risk Of Death By 38% In Endometrial Cancer Trial Compared To Chemo - Yahoo Finance
finance.yahoo.com - March 20 at 3:56 AM
Merck Keytruda Plus Eisais Lenvima Cuts Risk Of Death By 38% In Endometrial Cancer Trial Compared To Chemo - BenzingaMerck' Keytruda Plus Eisai's Lenvima Cuts Risk Of Death By 38% In Endometrial Cancer Trial Compared To Chemo - Benzinga
benzinga.com - March 19 at 10:15 PM
Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimers Disease by Dian-Tu - BenzingaEisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer's Disease by Dian-Tu - Benzinga
benzinga.com - March 16 at 8:21 AM
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimers Disease and Dementia at the 15th International Conference on Alzheimers and Parkinsons Disease - Yahoo Finance AustraliaEisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease - Yahoo Finance Australia
au.finance.yahoo.com - March 5 at 6:22 AM
Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy - Yahoo Finance AustraliaEisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy - Yahoo Finance Australia
au.finance.yahoo.com - February 22 at 5:35 PM
BIAL Takes the Lead in Europe for the Commercialisation of Epilepsy Treatment, Zebinix® (eslicarbazepine acetate), Expanding Neurology Footprint - Business WireBIAL Takes the Lead in Europe for the Commercialisation of Epilepsy Treatment, Zebinix® (eslicarbazepine acetate), Expanding Neurology Footprint - Business Wire
businesswire.com - February 17 at 8:34 PM
Merck/Eisais Keytruda-Lenvima Combo Tops Standard Of Care In Late-Stage Kidney Cancer Study - BenzingaMerck/Eisai's Keytruda-Lenvima Combo Tops Standard Of Care In Late-Stage Kidney Cancer Study - Benzinga
benzinga.com - February 16 at 10:33 PM
Merck/Eisais Keytruda-Lenvima Combo Tops Standard Of Care In Late-Stage Kidney Cancer Study - Yahoo FinanceMerck/Eisai's Keytruda-Lenvima Combo Tops Standard Of Care In Late-Stage Kidney Cancer Study - Yahoo Finance
finance.yahoo.com - February 16 at 5:33 PM
Merck/Eisais Keytruda-Lenvima Combo Tops Standard Of Care In Late-Stage Kidney Cancer StudyMerck/Eisai's Keytruda-Lenvima Combo Tops Standard Of Care In Late-Stage Kidney Cancer Study
finance.yahoo.com - February 16 at 5:33 PM
Eisai earnings: heres what Wall Street expectsEisai earnings: here's what Wall Street expects
markets.businessinsider.com - February 2 at 6:47 PM
Biogen Shares Jump After FDA Delays Aducanumab Decision By 3 MonthsBiogen Shares Jump After FDA Delays Aducanumab Decision By 3 Months
finance.yahoo.com - January 29 at 1:45 PM
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan - Yahoo Finance AustraliaEisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan - Yahoo Finance Australia
au.finance.yahoo.com - December 20 at 10:22 PM
Nikkei rallies to 29-year high, Honda leads carmakers on upbeat earningsNikkei rallies to 29-year high, Honda leads carmakers on upbeat earnings
finance.yahoo.com - November 8 at 11:43 PM
Biogens long and winding road in Alzheimers hits wallBiogen's long and winding road in Alzheimer's hits wall
seekingalpha.com - November 7 at 1:10 AM
FDA panel urges rejection of experimental Biogen Alzheimer’s drugFDA panel urges rejection of experimental Biogen Alzheimer’s drug
msn.com - November 6 at 8:09 PM
Biogen Trading Halted Ahead of FDA Meeting on Alzheimers DrugBiogen Trading Halted Ahead of FDA Meeting on Alzheimer's Drug
thestreet.com - November 6 at 10:08 AM
What Biogen Investors Should Know Ahead Of Adcom Meeting On Alzheimers CandidateWhat Biogen Investors Should Know Ahead Of Adcom Meeting On Alzheimer's Candidate
msn.com - November 3 at 6:36 PM
EMA accepts Biogen's Alzheimer's treatment aducanumab for reviewEMA accepts Biogen's Alzheimer's treatment aducanumab for review
finance.yahoo.com - October 30 at 6:22 PM
The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinsons Study, 2 Biotechs Make Wall Street DebutsThe Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
benzinga.com - October 30 at 1:22 PM
Eisai launches late-stage study of lorcaserin in severe type of epilepsyEisai launches late-stage study of lorcaserin in severe type of epilepsy
seekingalpha.com - September 30 at 10:12 AM
Keytruda/Lenvima combo shows positive action in range of cancersKeytruda/Lenvima combo shows positive action in range of cancers
seekingalpha.com - September 21 at 1:40 PM
European advisory group backs expanded use of Eisai epilepsy med FycompaEuropean advisory group backs expanded use of Eisai epilepsy med Fycompa
seekingalpha.com - September 18 at 9:03 AM
Anti-Amyloid Drugs: The Advantages Of Alzheons ALZ-801 Over Biogens AducanumabAnti-Amyloid Drugs: The Advantages Of Alzheon's ALZ-801 Over Biogen's Aducanumab
seekingalpha.com - August 27 at 8:47 AM
Eisai Receives Approval to Market Anticancer Agent Halaven(R) in AustraliaEisai Receives Approval to Market Anticancer Agent Halaven(R) in Australia
au.finance.yahoo.com - August 12 at 3:54 AM
Japan stocks edge up on weaker yen, stalemate in U.S. stimulus talks weighsJapan stocks edge up on weaker yen, stalemate in U.S. stimulus talks weighs
finance.yahoo.com - August 11 at 10:53 PM
Biogen Soars As FDA Accepts Alzheimers Drug For Review In Next Stage Of Aducanumab SagaBiogen Soars As FDA Accepts Alzheimer's Drug For Review In 'Next Stage Of Aducanumab Saga'
msn.com - August 7 at 3:48 PM
Biogen-Eisai Alzheimers Drug Gets FDA Priority ReviewBiogen-Eisai Alzheimer's Drug Gets FDA Priority Review
thestreet.com - August 7 at 10:46 AM
U.S. FDA accepts Biogen's marketing application for Alzheimer's drugU.S. FDA accepts Biogen's marketing application for Alzheimer's drug
finance.yahoo.com - August 7 at 10:46 AM
Japan shares hit 5-week high on vaccine, economic growth hopesJapan shares hit 5-week high on vaccine, economic growth hopes
finance.yahoo.com - July 15 at 7:44 AM
Biogen/Eisai's New BAN2401 Study for Alzheimer's BeginsBiogen/Eisai's New BAN2401 Study for Alzheimer's Begins
finance.yahoo.com - July 14 at 9:54 AM
Merck's Keytruda Combo Gets CRL for First-Line Liver CancerMerck's Keytruda Combo Gets CRL for First-Line Liver Cancer
finance.yahoo.com - July 9 at 1:37 PM
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For BankruptcyThe Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
www.msn.com - July 8 at 9:26 AM
New Strong Sell Stocks for July 6thNew Strong Sell Stocks for July 6th
finance.yahoo.com - July 6 at 8:58 AM
Should You Buy These 3 Stocks Tackling Alzheimers Disease?Should You Buy These 3 Stocks Tackling Alzheimer's Disease?
www.nasdaq.com - June 29 at 5:36 PM
Eisai Co. Ltd. ADREisai Co. Ltd. ADR
www.barrons.com - June 10 at 6:01 PM
Keytruda/Lenvima combo shows benefit liver and kidney cancersKeytruda/Lenvima combo shows benefit liver and kidney cancers
seekingalpha.com - May 29 at 9:46 AM
ESALY Eisai Co. Ltd. ADR (Sponsored)ESALY Eisai Co. Ltd. ADR (Sponsored)
www.nasdaq.com - May 23 at 11:52 PM
Biogen Delays Regulatory Filing For Approval Of Alzheimers Drug, Shares SlumpBiogen Delays Regulatory Filing For Approval Of Alzheimer's Drug, Shares Slump
www.benzinga.com - April 22 at 1:37 PM
Lantern Pharma on deck for IPOLantern Pharma on deck for IPO
seekingalpha.com - April 16 at 6:25 PM
The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus TestsThe Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests
www.benzinga.com - April 1 at 8:32 AM
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.